Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

RXC008

Source date not recordedAnalyse record ↗

GI-restricted pan-ROCK inhibitor with completed Phase 1 testing and a registered Phase 2 fibrosis study not yet recruiting.

Modality
oral gastrointestinal-restricted pan-ROCK inhibitor
Availability (US)
Phase 1 completed; Phase 2 fibrostenotic-Crohn's study registered as Not yet recruiting
Biomarkers
treatment-emergent adverse events; endoscopic stricture measurements; intestinal-fibrosis imaging; pharmacokinetics; tissue exposure
Hallmark targeted
extracellular-matrix remodeling, intestinal fibrosis, altered intercellular communication
Kind
investigational drug
Clinical trials
NCT07832435 — Phase 2, Not yet recruiting on September 22, 2026 update; estimated start October 1, 2026